Gonadotropin-releasing hormone agonist use before hysterectomy.

Stovall TG, Summit RL Jr, Washburn SA, Ling FW

American journal of obstetrics and gynecology1 Jun 1994Cited by 33 (Europe PMC)

PMID8203435DOI10.1016/s0002-9378(94)70350-7PepBankPUB-08203435

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with uterine size of 14 to 18 gestational weeks, leuprolide increased vaginal hysterectomy use versus no preoperative agonist.
In plain wordsIn patients with smaller uterine leiomyomas, vaginal hysterectomy was more common with leuprolide than without preoperative agonist.
Peptide
Leuprolide
Outcome
IncreaseVaginal hysterectomy
Study
n = 90
Comparator
No preoperative agonist
Outcome group
Surgical outcomes · Reproductive and sexual health
Studied dose
Dose not stated · 2 monthsAs given in this study (human).
Measurements
Vaginal hysterectomy
80%
leuprolide
Vaginal hysterectomy
13%
no preoperative agonist
Source sentences
Summary
Patients in group I who received preoperative agonist were more likely to undergo vaginal hysterectomy (80% vs 13%, p < 0.05) than were patients who did not receive preoperative agonist.
2 context sentences(design, population, supporting numbers)
Summary · context
Our purpose was to compare the effects of leuprolide acetate in patients with symptomatic uterine leiomyoma before hysterectomy.
Summary · context
Patients in both groups were randomized to either immediate hysterectomy or 2 months of preoperative gonadotropin-releasing hormone agonist.
Report a problemFND-0820343502
02HumanRandomized controlled trialEfficacy outcome
In patients with uterine size above 18 gestational weeks, surgical outcomes did not differ between leuprolide and immediate hysterectomy arms.
In plain wordsIn patients with larger uterine leiomyomas, surgical outcomes did not differ between leuprolide and immediate hysterectomy.
Peptide
Leuprolide
Outcome
No significant changeIntraoperative morbidity, blood loss, hospital stay and convalescence
Study
n = 60
Comparator
Immediate hysterectomy
Outcome group
Surgical outcomes · Reproductive and sexual health
Studied dose
Dose not stated · 2 monthsAs given in this study (human).
Source sentences
Summary
In group II, in spite of a mean uterine volume reduction of 51.3%, intraoperative morbidity, operative blood loss, hospital stay, and postoperative convalescence period did not differ between treatment arms.
2 context sentences(design, population, supporting numbers)
Summary · context
Our purpose was to compare the effects of leuprolide acetate in patients with symptomatic uterine leiomyoma before hysterectomy.
Summary · context
Patients in both groups were randomized to either immediate hysterectomy or 2 months of preoperative gonadotropin-releasing hormone agonist.
Report a problemFND-0820343504
03HumanNon-randomized trialEfficacy outcome
In patients with uterine leiomyoma and pretreatment hemoglobin below 11.0 gm/dl, hemoglobin increased significantly by at least 1.5 gm/dl after leuprolide.
In plain wordsIn patients with uterine leiomyoma and low hemoglobin before treatment, hemoglobin increased after leuprolide.
Peptide
Leuprolide
Outcome
IncreaseHemoglobin
Study
n: not reported in source
Outcome group
Blood counts and hematopoiesis · Reproductive and sexual health
Studied dose
Dose not stated · 2 monthsAs given in this study (human).
Measurements
Hemoglobin increase
≥ 1.5 gm/dl
pretreatment hemoglobin <11.0 gm/dl
Source sentences
Summary
All patients in the two groups with a pretreatment hemoglobin or = 1.5 gm/dl) in hemoglobin level.
2 context sentences(design, population, supporting numbers)
Summary · context
Our purpose was to compare the effects of leuprolide acetate in patients with symptomatic uterine leiomyoma before hysterectomy.
Summary · context
Patients in both groups were randomized to either immediate hysterectomy or 2 months of preoperative gonadotropin-releasing hormone agonist.
Report a problemFND-0820343501
04HumanNon-randomized trialEfficacy outcome
In patients with uterine size above 18 gestational weeks, mean uterine volume decreased by 51.3% with leuprolide.
In plain wordsIn patients with larger uterine leiomyomas, uterine volume decreased with leuprolide.
Peptide
Leuprolide
Outcome
DecreaseUterine volume
Study
n: not reported in source
Outcome group
Uterine volume · Reproductive and sexual health
Studied dose
Dose not stated · 2 monthsAs given in this study (human).
Measurements
Mean uterine volume reduction
51.3%
group II
Source sentences
Summary
In group II, in spite of a mean uterine volume reduction of 51.3%, intraoperative morbidity, operative blood loss, hospital stay, and postoperative convalescence period did not differ between treatment arms.
2 context sentences(design, population, supporting numbers)
Summary · context
Our purpose was to compare the effects of leuprolide acetate in patients with symptomatic uterine leiomyoma before hysterectomy.
Summary · context
Patients in both groups were randomized to either immediate hysterectomy or 2 months of preoperative gonadotropin-releasing hormone agonist.
Report a problemFND-0820343503

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.